Aperio Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Aperio Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-48,646	Closed	-$2.62M	–	2295
2017 Q4	$2.62M	Sell	48,646 -4,798	-9%	-$263K	0.01%	889
2017 Q3	$3.05M	Buy	53,444 +12,374	+30%	+$725K	0.02%	783
2017 Q2	$2.47M	Buy	41,070 +5,059	+14%	+$288K	0.02%	827
2017 Q1	$1.96M	Buy	+36,011	New	+$1.77M	0.01%	878

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Aperio Group's BIVV Position: Q1 2018 in Review

Aperio Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 48,646 shares — an estimated $2.62M sold.

Aperio Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $3.05M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Aperio Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Aperio Group sold 48,646 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $2.62M.
Aperio Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Aperio Group's Bioverativ Inc. Common Stock position peaked at $3.05M in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Aperio Group's 13F filing for Q1 2018, filed 8 May 2018.